480 related articles for article (PubMed ID: 29549464)
1. Effect of allopurinol on the glomerular filtration rate of children with chronic kidney disease.
Ghane Sharbaf F; Assadi F
Pediatr Nephrol; 2018 Aug; 33(8):1405-1409. PubMed ID: 29549464
[TBL] [Abstract][Full Text] [Related]
2. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5.
Liu X; Wang H; Ma R; Shao L; Zhang W; Jiang W; Luo C; Zhai T; Xu Y
Clin Exp Nephrol; 2019 Mar; 23(3):362-370. PubMed ID: 30291473
[TBL] [Abstract][Full Text] [Related]
3. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function.
Kanbay M; Huddam B; Azak A; Solak Y; Kadioglu GK; Kirbas I; Duranay M; Covic A; Johnson RJ
Clin J Am Soc Nephrol; 2011 Aug; 6(8):1887-94. PubMed ID: 21784838
[TBL] [Abstract][Full Text] [Related]
4. Time to target uric acid to retard CKD progression.
Kumagai T; Ota T; Tamura Y; Chang WX; Shibata S; Uchida S
Clin Exp Nephrol; 2017 Apr; 21(2):182-192. PubMed ID: 27339448
[TBL] [Abstract][Full Text] [Related]
5. Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease.
Levy G; Shi JM; Cheetham TC; Rashid N
Perm J; 2018; 22():17-142. PubMed ID: 30201087
[TBL] [Abstract][Full Text] [Related]
6. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
Lee JW; Lee KH
Int Urol Nephrol; 2019 Mar; 51(3):467-473. PubMed ID: 30604229
[TBL] [Abstract][Full Text] [Related]
7. The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.
Hosoya T; Kimura K; Itoh S; Inaba M; Uchida S; Tomino Y; Makino H; Matsuo S; Yamamoto T; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H
Trials; 2014 Jan; 15():26. PubMed ID: 24433285
[TBL] [Abstract][Full Text] [Related]
8. Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease.
Peng YL; Tain YL; Lee CT; Yang YH; Huang YB; Wen YH; Hsu CN
Sci Rep; 2020 Jul; 10(1):10734. PubMed ID: 32612180
[TBL] [Abstract][Full Text] [Related]
9. Benefits of Allopurinol Treatment on Blood Pressure and Renal Function in Patients with Early Stage of Chronic Kidney Disease.
Satirapoj B; Wirajit O; Burata A; Supasyndh O; Ruangkanchanasetr P
J Med Assoc Thai; 2015 Dec; 98(12):1155-61. PubMed ID: 27004299
[TBL] [Abstract][Full Text] [Related]
10. Febuxostat is superior to allopurinol in delaying the progression of renal impairment in patients with chronic kidney disease and hyperuricemia.
Zhang X; Wan D; Yang G; Peng Q; Wang X
Int Urol Nephrol; 2019 Dec; 51(12):2273-2283. PubMed ID: 31646459
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Allopurinol on Renal Function.
Krishnamurthy A; Lazaro D; Stefanov DG; Blumenthal D; Gerber D; Patel S
J Clin Rheumatol; 2017 Jan; 23(1):1-5. PubMed ID: 28002149
[TBL] [Abstract][Full Text] [Related]
12. The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia.
Tsuji T; Ohishi K; Takeda A; Goto D; Sato T; Ohashi N; Fujigaki Y; Kato A; Yasuda H
Clin Exp Nephrol; 2018 Dec; 22(6):1300-1308. PubMed ID: 29700702
[TBL] [Abstract][Full Text] [Related]
13. Effect of Febuxostat versus Allopurinol on the Glomerular Filtration Rate and Hyperuricemia in Patients with Chronic Kidney Disease.
Nagaraju SP; Shenoy SV; Rao I; Prabhu RA; Rangaswamy D; Bhojaraja MV; Guddattu V
Saudi J Kidney Dis Transpl; 2023 Jul; 34(4):279-287. PubMed ID: 38345582
[TBL] [Abstract][Full Text] [Related]
14. Allopurinol Against Progression of Chronic Kidney Disease.
Golmohammadi S; Almasi A; Manouchehri M; Omrani HR; Zandkarimi MR
Iran J Kidney Dis; 2017 Jul; 11(4):286-293. PubMed ID: 28794291
[TBL] [Abstract][Full Text] [Related]
15. Prednisone in Uric Acid lowering in Symptomatic Heart Failure Patients With Hyperuricemia (PUSH-PATH) study.
Liu C; Zhao Q; Zhen Y; Gao Y; Tian L; Wang L; Ji L; Liu G; Ji Z; Liu K
Can J Cardiol; 2013 Sep; 29(9):1048-54. PubMed ID: 23395281
[TBL] [Abstract][Full Text] [Related]
16. Preservation of renal function during gout treatment with febuxostat: a quantitative study.
Whelton A; MacDonald PA; Chefo S; Gunawardhana L
Postgrad Med; 2013 Jan; 125(1):106-14. PubMed ID: 23391676
[TBL] [Abstract][Full Text] [Related]
17. Elevated uric acid level as a significant predictor of chronic kidney disease: a cohort study with repeated measurements.
Chou YC; Kuan JC; Yang T; Chou WY; Hsieh PC; Bai CH; You SL; Chen CH; Wei CY; Sun CA
J Nephrol; 2015 Aug; 28(4):457-62. PubMed ID: 25410145
[TBL] [Abstract][Full Text] [Related]
18. Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients.
Kose E; An T; Kikkawa A; Matsumoto Y; Hayashi H
Biol Pharm Bull; 2014; 37(2):226-31. PubMed ID: 24492719
[TBL] [Abstract][Full Text] [Related]
19. Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease.
Sakai Y; Otsuka T; Ohno D; Murasawa T; Sato N; Tsuruoka S
Ren Fail; 2014 Mar; 36(2):225-31. PubMed ID: 24152124
[TBL] [Abstract][Full Text] [Related]
20. Hyperuricemia and Progression of CKD in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort Study.
Rodenbach KE; Schneider MF; Furth SL; Moxey-Mims MM; Mitsnefes MM; Weaver DJ; Warady BA; Schwartz GJ
Am J Kidney Dis; 2015 Dec; 66(6):984-92. PubMed ID: 26209544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]